As populations age, the global health burden of neurodegenerative diseases is intensifying. Currently, an estimated 55 million people worldwide are living with dementia, with approximately 35 million affected specifically by Alzheimer’s disease, and that number is projected to triple by 2050, according to the WHO. Meanwhile, conditions like ALS, Parkinson’s, and spinal cord injuries continue … The iPSC & Small Molecule Convergence: Redefining What’s Possible in CNS Drug Development Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.